Publications

Avalyn is developing inhaled formulations of approved medications for rare respiratory diseases. Our initial focus is on treating Interstitial Lung Diseases (ILD), including Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF) and rare diseases that dramatically impact patient quality of life.

December 12, 2022

Inhaled Pirfenidone Is Associated With Better Quality of Life Scores in Idiopathic Pulmonary Fibrosis

February 6, 2022

Inhalation: A Means to Improve Existing IPF Therapies

March 24, 2021

Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis

August 22, 2020

Inhaled Nintedanib Is Well-Tolerated and Delivers Key Pharmacokinetic Parameters Required To Treat Bleomycin-Induced Pulmonary Fibrosis

August 1, 2020

Inhalation: A Means to Explore and Optimize Nintedanib’s Pharmacokinetic/codynamic Relationship

February 6, 2020

Improvement in HRCT Lung Fibrosis With Inhaled Pirfenidone Is Associated With Better Health-Related Quality of Life Scores in Patients With IPF

January 30, 2020

Direct Lung Administration of Nintedanib Reduces Lung Fibrosis in a Multi-Challenge Bleomycin Rat Model

January 4, 2020

A Randomized Double-Blind Placebo-Controlled Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone

December 12, 2019

Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis

February 6, 2018

Pharmacokinetics and Safety of Pirfenidone Following Inhaled Delivery to Sheep: A Viable Approach to Treating Idiopathic Pulmonary Fibrosis

February 5, 2018

Fibroblast–matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype

February 6, 2015

Assessment of Regional Lung Deposition of Aerosol Aerodone in IPF Patients Using Functional Respiratory Imaging

January 10, 2014

Inhalation Improves Pirfenidone Animal Efficacy Through Superior Pulmonary and Vascular Pharmacokinetics